To gauge the ability of DNAm profiling to predict BCBM subtypes, we included four additional patients without prior HR and/or HER2 IHC evaluation of their BM specimens, which were treated based on IHC evaluation of their primary breast cancer tumors and/or extra-cranial metastases. This evidence concerns the gene ERBB2 and breast cancer.